You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Low-Cost, Regenerable Air Filter for Efficient Gaseous Pollutants Removal
SBC: PRECISION COMBUSTION, INC. Topic: DPrecision Combustion, Inc. (PCI) proposes to develop a regenerable, low-cost, high-efficiency pollution control technology for removal of gaseous pollutants from contaminated air streams. This innovative air filter technology will combine our novel proprietary Microlith® support elements with sorbent nanomaterials that can be tailored to capture a variety of targeted gaseous pollutants. Originall ...
SBIR Phase I 2014 Environmental Protection Agency -
Novel flavonoids as anti-inflammatory agents in alcoholism
SBC: NAPROGENIX, INC. Topic: NIAAADESCRIPTION (provided by applicant): Flavonoids are ubiquitous secondary metabolites in plants with many known health benefits, which are mostly ascribed to their potent anti-oxidant activity. However, a search for novel nicotinic ligands, using high throughput pharmacological screening of a native plant extract library, and subsequently a pure flavonoid library, led to the highly surprising con ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Formulation of LbL microparticle vaccine in microneedle array for intradermal del
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDAbstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid Point-of-Care Salivary Diagnostic for Periodontal Health
SBC: INNOVATIVE DIAGNOSTICS, INC. Topic: NIDCRDESCRIPTION (provided by applicant): The dental profession has searched for many years for additional real time chair-side measures to provide objective measures to aid in the monitoring of periodontal health and early diagnosis of disease. Research efforts have produced solid evidence that constituents present in saliva can provide important complimentary diagnostic information, and have the po ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel reporter cell lines for neurotoxicant assays
SBC: TRANSPOSAGEN BIOPHARMACEUTICALS, INC. Topic: NIEHSDESCRIPTION (provided by applicant): While it has been demonstrated that gene mutations are associated with an increasing number of neurodegenerative syndromes, environmental neurotoxicants remain a key factor in the etiology of many such diseases. For example, exposure to pesticides such as maneb and paraquat increase the risk of developing Parkinson's disease. Unfortunately, there is no opt ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Sterculic Acid Analogs to Inhibit Macular Degeneration
SBC: L2 DIAGNOSTICS LLC Topic: NEIABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Hydrocyanine Probes for the Accurate Detection of Reactive Oxygen Species
SBC: LI-COR BIOSCIENCES, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Reactive oxygen species (ROS) are involved in numerous cell-signaling pathways. They have been implicated in over 150 diseases including cancer, arthritis, Parkinson's disease, diabetes, myocardial infarction and atherosclerosis. The need to understand the role of ROS in these processes is evidenced by the 80,000 publications in this field during the last ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
System for Multiplex Protein:Protein Interaction Studies Modeled with Antibodies
SBC: AXIOMX INC Topic: NIGMSDESCRIPTION (provided by applicant): The overarching goal of Phase I is to produce a method that will generate, identify and clone a catalog of protein-protein interactions in a single rapid experiment. In this proposal we will model the technology using antibody-antigen interactions. Recombinant antibody libraries against a proteome could be produced prior to any need, and then desired affinity r ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of TransApical to Aorta Double Lumen Cannula for a Neonate LVAD
SBC: W-Z BIOTECH LLC Topic: NHLBIDESCRIPTION (provided by applicant): Left ventricular assist device (LVAD) support allows the neonate with congenital heart disease or cardiomyopathy to grow to a larger body weight that is more feasible for complex surgical correction or heart transplant.A paracorporeal LVAD, the Berlin heart ExCor, is FDA-approved for pediatric application. Although this device is outside the body, the outflow g ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health